Search

Oral Therapies in Lymphoma and Chronic Lymphocytic Leukemia

The Lymphoma Research Foundation (LRF) is a recognized leader in the national dialogue around the use of oral therapies to treat cancer. In addition to creating unique patient education programs and resources on the topic, in 2015 the Foundation convened a first-of-its-kind meeting to identify specific challenges facing the research and patient communities related to the development, optimization, and utilization of oral lymphoma/CLL therapies. The Foundation convened key opinion leaders from across the country to discuss these emerging issues, and the meeting’s resulting white paper outlined strategies to improve clinical studies as well as outcomes and quality of life for lymphoma patients.

On October 19, 2017, the Foundation convened a follow-up workshop in New York City specifically focused on treatment adherence, a significant recommendation identified in the original workshop proceedings. Lymphoma/CLL patient nonadherence to oral anti-cancer agents is a complex problem which can contribute to poor treatment outcomes and increased consumption of health care resources.

To learn more about these scientific meetings and access related materials, please view the content and links below.


Adherence and Oral Therapies in Lymphoma and Chronic Lymphocytic Leukemia (CLL)

In October 2017 LRF convened a workshop focused on the utilization of oral oncolytics, Adherence and Oral Therapies in Lymphoma and CLL. The workshop’s goal was to gain an in-depth understanding of the primary causes of nonadherence among lymphoma and CLL patients, and to explore related adherence interventions and tools. The meeting was attended by a diverse group of stakeholders, including members of LRF’s Scientific Advisory Board. Based on the workshop findings, an action plan and white paper will be developed to prioritize and identify adherence-focused research opportunities.

To view select presentations from the workshop, click the links below:
Adherence and Oral Therapies in Lymphoma and CLL LRF Workshop - Part I
Adherence and Oral Therapies in Lymphoma and CLL LRF Workshop - Part II


Oral Therapies in Lymphoma: Opportunities and Challenges in Research and Treatment

In September 2015, The Lymphoma Research Foundation (LRF) convened scientists, clinicians, advocates, pharmaceutical industry representatives, and federal lawmakers and regulators for a workshop on Oral Therapies in Lymphoma. Lymphoma and chronic lymphocytic leukemia (CLL) are a complex group of malignancies traditionally managed by cytotoxic chemotherapy, immunotherapy, radiation treatment, and, in some cases, by high dose chemotherapy and stem cell transplantation. Recognizing that cancer care has entered a new era in which targeted oral anti-lymphoma agents are quickly changing treatment paradigms and providing a unique opportunity to improve patient outcomes and survival, LRF hosted the meeting to identify the specific challenges facing the scientific and patient communities related to the development, optimization, treatment adherence, and access to lymphoma oral therapies.

The workshop engaged and informed key stakeholders of these challenges and the day-long discussion helped to shed a light on priority action items for further investigation and investment.

The Foundation published the White Paper, Oral Therapies in Lymphoma: Opportunities and Challenges in Research and Treatment, contributing to the ongoing discussion on the growing importance of the role of oral therapies in the treatment of cancer. The paper outlines the key issues discussed during the workshop, and opportunities and challenges facing patients, the cancer care team, and the research community with respect to the development, accessibility and deliver of oral agents to patients with lymphoma and other blood cancers. Download the White Paper today.